Analyzing Exelixis Stock Performance – A Brief Overview

By Scott Lee • Wednesday, July 16 10:05 • Permanent Link

Exelixis logged a 0.6% change during today's morning session, and is now trading at a price of $44.3 per share. The S&P 500 index moved 0.0%. EXEL's trading volume is 124,556 compared to the stock's average volume of 3,320,556.

Exelixis trades -0.38% away from its average analyst target price of $44.47 per share. The 19 analysts following the stock have set target prices ranging from $29.0 to $60.0, and on average have given Exelixis a rating of buy.

Anyone interested in buying EXEL should be aware of the facts below:

Exelixis's current price is 155.8% above its Graham number of $17.32, which implies that at its current valuation it does not offer a margin of safety
Exelixis has moved 100.3% over the last year, and the S&P 500 logged a change of 10.6%
Based on its trailing earnings per share of 2.19, Exelixis has a trailing 12 month Price to Earnings (P/E) ratio of 20.2 while the S&P 500 average is 29.3
EXEL has a forward P/E ratio of 26.1 based on its forward 12 month price to earnings (EPS) of $1.7 per share
Its Price to Book (P/B) ratio is 5.72 compared to its sector average of 3.19
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
Based in Alameda, the company has 1,147 full time employees and a market cap of $12.08 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.